draft edition

SCIENTIA VINCERE

cgt-development

GLOBAL INNOVATION SUMMIT 2025

21-22 MAY 2025 BOSTON USA

CELL & GENE INNOVATION OVERCOMING CURRENT LIMITATIONS IN CGT BIOPROCESSING, MANUFACTURING, SUPPLY CHAIN & COMMERCIALIZATION

MANUFACTURING AND BIOPROCESS

REVOLUTIONISING SUPPLY & VALUE CHAIN AUTOMATION & ORCHESTRATION: Standardize
Best Practice in Planning, Communication & Scale Up to Consistently Deliver Safely, on Time & in a Cost-Effective Process

DOWNSTREAM MANUFACTURING OF GENE THERAPY VECTORS:
Viral Vector Development, Manufacturing, and Process Intensification. Accelerated Development, Manufacturing and Monitoring of Viral Vectors.

SUPPLY CHAIN AND LOGISTIC

REVOLUTIONISING SUPPLY & VALUE CHAIN AUTOMATION & ORCHESTRATION:
Managing product quality across an increasingly diverse and global manufacturing network

QUALITY COMPLIANCE COMMERCIALIZATION

INDUSTRIALIZATION OF AUTOLOGOUS AND ALLOGENEIC GENETICALLY MODIFIED THERAPIES.
Lesson learnt and the road to enabling standardisation

PRICING AND MARKET ACCESS

OVERVIEW OF AVAILABLE REGULATORY PATHWAYS TO ACCELERATE DEVELOPMENT FOR ADVANCED THERAPIES
Strategies For Commercial Success, getting ahead the upcoming challenges.

Roberto Nitsch
Director
Gene Therapies
AstraZeneca

Shawn Liu, Ph.D
President & CEO
Avirmax Inc

James Warren
VP, Pharmaceutical Development
Ultragenyx

Vladimir Slepushkin
Executive Director, Vector Technology
Autolus

INNOVATION PARTNERS

ThermoFisher SCIENTIFIC · SARTORIUS · BIA separations (BIA Separations is now part of Sartorius) · MilliporeSigma · SGS · CELLARES · OQSIE

21st & 22nd MAY 2025 US
cgt-development.com

MEDIA

GEN Genetic Engineering & Biotechnology News · BioProcess INTERNATIONAL

CONTINUALLY PUSHING THE BOUNDARIES OF INNOVATION
CELL AND GENE THERAPY CAPABILITIES

The cgt-development, Global Innovation Summit 2025 is the Leading Cell & Gene Therapy leaders forum; dedicated to innovation, advancing production & commercialisation

Innovation is the process of turning new ideas into value. Recent years have seen Cell & Gene Therapies potential, realised into new products, services and methods like never before; along with creativity and invention to make the practical steps necessary for the adoption of next generation technologies and strategies and, in turn, laying the foundation for continued industry growth. Many leaders in Cell & Gene Therapies communities have priorities innovation as a key goal for long-term productivity and economic growth knowing that innovative firms significantly outperform non-innovators, in terms of both revenue and employment growth

Proudly presenting the highly anticipated and exciting 2025 program, comprised of renowned world class speaker and industry thought leaders. Following comprehensive research using data from attendee surveys results, investment analytics platforms and media partners, undertaken with an expert panel advisory board. The program is rich with cutting-edge content on innovation and pivotal breakthroughs; giving you insight on the latest industry trends and technologies impacting Cell & Gene Therapies.

The leaders networking forum set to help pioneering professionals boost success and growth by providing a robust modern era leaders event platform that is highly informative and delivers a dynamic environment to benchmark, learn, engage, debate, procure and interact at the highest level. Make the right deals, with the right partners at the right time utilising a networking platform; designed particularly for decision makers to enhance overall experience and provide specialist business information.

INNOVATE - COLLABORATE - ADVANCE

Revolutionize Your Cell, Gene and CAR-T Programs

Network with the world's smartest leaders to share experience, ideas, innovations and expertise.

The CGT-development Innovation Summit 2025 is a leading executive gathering committed to creating an advanced networking platform to increase innovation and collaboration within the Cell & Gene Therapy area. Our unique model is designed particularly to complement networking and communication exclusively for decision makers to enhance overall experience and provide specialist business information.

Overcome key challenges:
Ensuring technological and operational supremacy and retain success with proven next generation strategies and approaches streamlined to obtain seamless integrated success in Cell & Gene Therapy development life-cycle from discovery in the lab to clinical and commercial scale production.

60+
DISTINGUISHED SPEAKERS

18
HOURS OVER 2 DAYS

150
COMPANIES

200+
INDUSTRY LEADERS

Alain Bernard Ph.D
SVP Technical Operations
UCB

Manal Morsy, MD, PhD, MBA
EVP, Head of Global Regulatory Affairs
Athersys

Dave Kolwyck
VP Manufacturing Science, Raw Materials
Biogen Idec

cgt development
GLOBAL INNOVATION CONGRESS

From interactive workshops, insightful panel discussions and ground-breaking keynotes, The program is specifically curated for you to make the most of your time at the summit.

- World Class Leading Speakers
- Leaders Panel Discussions
- Industry Leading Distinguished Keynotes
- One-to-One Meetings
- 10 Streams of Content
- Exhibition Showcases
- Interactive Round Tables
- Breakthrough Innovation Spotlights
- Peer-to-Peer In-Person & Digital Networking
- Champagne Reception
- Gala Dinner & Networking Lunches
- Breakthrough Case Studies

cgt-development.com
Tel: +44 203 699 8500
Email: cgtdev@wwresearch.net

ADVANCING vision into Reality

cgt-development

GLOBAL INNOVATION SUMMIT

Delegates typically include CEO,CMO, CSO, VP's, Directors, General Managers, and Heads of the following titles:

> **Content is rich with cutting edge strategic intelligence and technological innovation**

Keynote Speaker

Uwe Gottschalk
Chief Technology Officer

Lonza

- Cell and Gene Manufacturing
- Patient Access
- Cell & Gene Bioprocess
- Investigational Material Supply Chain
- Personalized Medicines
- AAV Viral Vector
- Next Gen Facility Design
- Immunotherapy Oncology
- Gene Editing
- Gene Therapy for Rare Diseases
- Stem Cells & Regenerative Medicine
- Regulatory Affairs
- Biomedical Engineering
- Digitalization \ Automation
- Scale-Up Strategies
- Clinical CART
- Tissue Engineering
- Pricing & Reimbursement
- Emerging Therapies
- Collaboration/ Outsourcing

THEMES IN DISCUSSION

The CGT-development Innovation Summit brings you the latest Cell, Gene & CAR-T Production Technologies and Commercialization Strategies. Themes for 2025 include:

- **Innovations in Process Development and Manufacturing Driving the Future of Cell & Gene Therapy development:** Avoid pitfalls and reduce bottlenecks, implementing new breakthrough processing methodologies, technologies and approaches to improve quality, yield and capacity.

- **Understanding all strategic options in an unprecedented era of expedited regulatory pathways:** Examining and defining the potential value for industry in accelerated development and conditional approval pathways from around the lobe.

- **Novel Gene Editing Applications in CART:** Understand next generations technologies in adoptive T cell Immunotherapy.

- **High Yielding AAV Platforms for Gene Therapy**: Examining continued innovation in Gene therapies.

- **Novel AAV Capsids for Gene Therapy:** Discovery, Characterization and Manufacturing.

- **Enabling more Precise, Efficient and Safer Genome Editing & Quantifying its Outcomes:** Innovation in repurposing of CRISPR-Cas 9 and all its variants. NextGen tools for on and off target effects when using different enzymes & variants.

- **Fundamental evolution to meet ATMP Quality and Process Challenges:** Implementation of next generation digital bioprocessing 4.0 and integrating automation technology for Increased GMP compliance and consistency. Enabling acceleration of processing research and scale-up considerations.

- **Will Allogeneic Replace Autologous Therapies?** Current industry trends and latest technological breakthroughs.

- **Novel Gene Editing Applications in CART:** Understand next generations technologies in adoptive T cell Immunotherapy

- **CAR and T CELL Therapies:** Pioneering point of care with innovative manufacturing and commercialization strategies: Revolutionizing cell and gene engineering - ground breaking autologous and allogeneic treatments for blood borne and solid tumours.

- **Achieving commercial scalability with 'facilities of the future' in patient-specific therapies:** Develop a "fit-for-purpose" development pathway that is associated with "faster to market" options for clinical development.

- **Technologizing ATMP/Cell and Gene Therapy:** Lentiviral vector manufacturing and analytics – opportunities, challenges and ways forward. The use of high-throughout technologies to facilitate cell line characterization and development, Evaluation of novel harvest methods for the clarification of cell culture material, Delivering a globally compliant allogeneic cell therapy - setting the benchmark.

PROGRAM CHAIRMAN

Dr. Aleš Štrancar
Managing Director
BIA Separations,
part of Sartorius Group

INNOVATION SPOTLIGHTS

ACCESS THE RIGHT INTELLIGENCE TO DESIGN YOUR FUTURE WITH CONFIDENCE

FUNDAMENTAL EVOLUTION TO MEET ATMP QUALITY AND PROCESS CHALLENGES

NEXT GEN TECHNOLOGY CELL & GENE THERAPY FACILITY DESIGN

REGULATORY PATHWAY TO COMMERCIAL SUCCESS

SUPPLY CHAIN AND LOGISTIC

MilliporeSigma

TBA

Automation technology for Increased GMP compliance and consistency. Enabling acceleration of processing research and scale-up considerations.

increased GMP compliance and consistency. Enabling acceleration of processing research and scale-up considerations. Overcoming regulatory barriers in manufacturing Cell & Gene Therapies updates and pain points: Developing a robust, defendable and practical control strategy to reduce cost and decrease regulatory overhead.

Guillaume Plane
Global Development
End-to-End Solutions
Millipore Sigma

Overcoming challenges with multi-product capability, moving towards flexible manufacturing, automated processing and systems implementation.

Achieving commercial scalability with ‘ facilities of the future’ in patient-specific therapies:

Develop a “fit-for-purpose” development pathway that is associated with “faster to market” options for clinical development.

TBA

Understanding all strategic options in an unprecedented era of expedited regulatory pathways: Examining and defining the potential value for industry in accelerated development and conditional approval pathways from around the globe.

Development Cell Therapy Scale-Up Strategies For Commercial Success: Getting ahead the upcoming challenges. Recalibration in development of reimbursement model for therapies that go beyond the traditional approach To disease treatment.

TBA

Overcoming challenges with ageing plants moving towards flexible manufacturing, automated processing and systems implementation

Achieving commercial scalability with ‘facilities of the future’ in patient-specific therapies:

Develop a “fit-for-purpose” development pathway that is associated with “faster to market” options for clinical development.

PROGRAM: DAY 1 MORNING - HARBOUR VIEW BALLROOM

08:00 **Registration And Networking Breakfast**

08:50 **Chairman's Welcoming And Opening Address**

Chairperson's Congress Address
Evolution v Revolution: which changes are driving our industry and where are they leading us to?

09:00 **Opening Keynote**

Streamlining Cell and Gene Therapy Production:
Next-Generation Process Development and Manufacturing Strategies for Enhanced Efficiency and Cost Savings

TBA

09:45 **Evolution of Biologics Development**

Henrick Anderson
VP Biologics Development
Bristol Myers Squibb

10:15 **Exhibitors Innovation Spotlights**

An Introduction and profile summary from BioManufactuting Global Innovation Exhibitors

---

10:30 **Morning Refreshments - Served at the Exhibition Area**

10:45 **Developing a robust, defendable and practical control strategy to reduce cost and decrease regulatory overhead**

Dr Alain Bernard
VP Tech Operation
UCB Pharma

11:15 **Fast AAV manufacturing process development by using dedicated HPLC system** - Fast and reliable in HPLC methods to allow for process optimization and assessing the purity of the final product using PATfix system will be presented.

Ales Strancar
Managing Director
SARTORIUS | BIA
BIA Separations is now part of Sartorius

11:45 **Smart manufacturing approaches in facilities design/upgrades:** Overcoming challenges with ageing plants moving towards flexible manufacturing, automated processing and systems implementation

TBA

Ballroom: Consitution

12 :15

Ballroom: Faneuil

PROCESS DEVELOPMENT & COMMERCIAL STRATEGIES

TBA

Title:
From cells to purified capsids: How to develop a scalable rAAV process

ROBOTICS AND ASEPTIC FILLING

Keith Dodson
Vice President of
Global Business Development

Reinventing Your Aseptic Processing with Flexible Robotic Manufacturing.
Learn about putting quality first in aseptic fill-finish using the newest technologies in flexible robotic manufacturing.

Trusted partner for aseptic processing solutions

12:45 - 14:15 Networking Lunch - Served at the Exhibition Area - Live Innovation Showcase Demos

Pre-Arranged One to One Boardroom Meeting

Allocated Board Rooms. All delegates without meetings can go to the exhibition area to be served lunch and network.

Pre-Scheduled Meeting 1 - 13:00

Pre-Scheduled Meeting 2 - 13:15

Pre-Scheduled Meeting 3 - 13:30

PROGRAM: DAY 1 AFTERNOON - SESSIONS AND WORKSHOPS

14:15

QUALITY AND COMPLIANCE COMMERCIALIZATION	CELL THERAPY	BIOPROCESSING & MANUFACTURING
STREAM KEYNOTE	**STREAM KEYNOTE**	**STREAM KEYNOTE**
Manal Morsy, MD, PhD, MBA EVP, Head of Global Regulatory Affairs	**TBA**	**TBA**
Expedited regulatory pathways from bench to market • Expedited Development Pathways • Expedited Regulatory Review Pathways • Expedited Regulatory Approval Pathways	Revolutionizing Autologous Cell Therapy Production: An Autonomous Biomanufacturing Platform for Scalable and Efficient Generation of iPSC-Derived Therapies	Streamlining Recombinant Adeno-Viral Vector Production: Leveraging Continuous Processing to Intensify Downstream Manufacturing and Enhance Efficiency

14:45

TBA	**Jessica Rage** Vice President Global Clinical Oncology	**Chao Huang, Ph.D.** Director Downstream Process Development
Adoptive T cell immunotherapy business models: Who has the lead in removing barriers to commercial success? Addressing the most pressing challenges facing the adoptive T cell therapy space today. Balancing regulatory requirements with process optimization for commercial feasibility in advanced stage T-Cell therapy products.	Immunotherapy and targeted therapy spheres: Which combination therapy strategies will help realize the full potential? Honing combination therapy clinical strategies involving CAR T cell and TCR immunotherapy products candidate.	Global Strategy to Enrich Full Capsids in Adeno-associated Viral Vector Based Gene Therapy Downstream Process Development.

15:15 **Afternoon Refreshments - Served at the Exhibition Area**

14:45

Dr. Tom Spitznagel, SVP, BiopPharmaceutical Development and Manufacturing	**John Tomtishen** Vice President Operations	**David Gruber** Director BioProcess Development
Evolution of a Robust Bispecific DART® Molecule Manufacturing Platform at MacroGenics	Innovating the Cell Therapy Manufacturing Paradigm • Are we meeting the needs of our patients? • What does the industry need? • How can we change the manufacturing paradigm to meet the needs of our patients?	New developments in chromatography: Overcoming current Challenges in developing Purification Platforms to alleviate Bottlenecks. How will this shape the future of protein purification?

PROGRAM: DAY 1 AFTERNOON STREAMS

Ballroom: Consitution

QUALITY AND COMPLIANCE

16:00

Chun Zhang
Snr. Director, Manufacturing Sciences & Operations Support

Creating patient-specific manufacturing system for commercial production: Enabling commercialisation by Innovation and out of the box thinking.

Ballroom: Faneuil

CELL THERAPY

Vladimir Slepushkin
Executive Director
Vector Technology

Gene edited ex vivo cell therapy accelerating viral vector.

Development of retroviral and lentiviral vectors for CAR-T therapy.

Ballroom: Quincy

PURIFICATION

David Roush
Principal Scientist
Purification

Leveraging technology innovation to overcome the direct impact of high titer processes In downstream processing.

GLOBAL LEADERS AUDIENCE INTERACTIVE PANEL DISCUSSION

16:30 **Learn, Debate And Bench Mark With Some Of The Most Influential Leaders In Biologics Manufacturing Globally**

KEY TOPICS OF DISCUSSIONS

- Examining the shortages in manufacturing capacity - A global problem with local consequences
- Achieving commercial scalability with 'facilities of the future' in patient-specific therapies:
- Pragmatic Implementation of Single-use Technologies to Reduce the Time and Resource Required to Deliver Clinical Supply.
- Preventing product variation and maintaining quality (Risk management strategies, raw material qualification, QbD)
- -Successful tech transfer of gene and cell therapy products: exploring the differences/risks particular to these products.

Have a question of discussion or debate for the leaders panel discussion? Use the interactive features interface and join in.

Dr. Tom Spitznagel

Senior Vice President
BioPharmaceuitcal
Development

MacroGenics

Dr. Aleš Štrancar

Managing Director

SARTORIUS | BIA separations

BIA Separations is now part of Sartorius

Roman Necina

Chief Technology
Officer

HOOKIPA PHARMA

Henrick Anderson

Vice President
Biologics Development

Bristol Myers Squibb®

TBA

Dave Kolwyck

Vice President
Manufacturing Science
Raw Materials

Biogen

PROGRAM DAY 1: EVENING - CHAIRMAN'S CLOSING REMARKS & NETWORKING GALA

17:15 **Day One Chairmans Closing remarks**

Ales Strancar
Managing Director

SARTORIUS | BIA separations

BIA Separations is now part of Sartorius

17:25 **Champagne Reception - Exhibition Area**

SARTORIUS | BIA separations

BIA Separations is now part of Sartorius

NETWORKING GALA DINNER

18:00 **Harbour View Ballroom**

Finishing off the program on day one the champagne reception and gala dinner provides the perfect setting to following on from networking encounter's throughout the day, discuss development opportunities with familiar peers or to just simply enjoy the food and evaluate what you've learnt throughout the day in the finest environment corporate hospitality has to offer. The winner of the business card lucky dip will also be announced giving you the opportunity to win a great prize.

Gala Dinner Hosted BY BIA Separations

SARTORIUS | BIA separations

BIA Separations is now part of Sartorius

End of Day 1

PROGRAM: DAY 2 MORNING - KEYNOTES

HARBOUR VIEW BALLROOM

09:00	**Day 2 Opening Address**	**TBA**
09:15	**Evaluating NextGen Technology:** Accelerating progress in a slow moving industry trapped between regulatory constraints and innovation.	**Lada Laenen, Sc.D.** SVP, Global Head Manufacturing Sciences and Technology GSK
09:45	**Quality as a Culture** Establishing a quality mindset across manufacturing and operations. Examining the cost of compliance and striking a careful balance between quality and cost management	**TBA**
10:30	**Morning Refreshments - Served at the Exhibition Area**	
10:45	**End-to-End Solutions Considering New Trends in Biomanufacturing:** The current state of biomanufacturing, from DNA to market approval, considering the way a key supplier can support drug makers to the fullest, thanks to a deep understanding of the trends that could affect our industry in the midterm, including growth of the pipelines, strengthening of regulations, and acceleration of time lines, for development as well as for the set-up of capabilities·	**Guillaume Plane** Global Development and Marketing Manager BioReliance® End-to-End Solutions. MilliporeSigma
11:15	**Successful tech transfer strategies; particularly in current climate of M&As:** effectively bridging the functions of manufacture, process development and quality Strategies in knowledge management and technology transfer.	**TBA**
11:45	**Use of High Throughput Technologies for Process Characterization and Process Validation**	**TBA**

NETWORKING LUNCH & THEMED DISCUSSION GROUPS

12:00 -13:30 **Disscussion groups and Networking Lunch Served in Ballroom B**

Pre-Arranged One to One Boardroom Meeting

Allocated Board Rooms. All delegates without meetings can go to the Ballroom to be served lunch and participate in themed discussion groups.

Pre-Scheduled Meeting 4 - 12:30 **Pre-Scheduled Meeting 5 - 12:45** **Pre-Scheduled Meeting 6 - 13:00** **Pre-Scheduled Meeting 7 - 13:45**

AUTOLOGUS CELL THERAPY PRODUCTION

Innovating the Cell Therapy Manufacturing Paradigm

- Are we meeting the needs of our patients?
- What does the industry need?
- How can we change the manufacturing paradigm to meet the needs of our patients?

CELLARES

TBA

AAV VECTOR PURIFICATION

Global Strategy to Enrich Full Capsids in Adeno-associated Viral Vector Based Gene Therapy Downstream Process Development.

Purolite Life Sciences

TBA

AAV VECTOR CHARACTERIZATION

-

TBA

REGENERATIVE MEDICINES

.

TBA

PRICING & REIMBURSEMENT

TBA

DECENTRALIZED CLINICAL MAUFACTURING

Innovating the Cell Therapy Manufacturing Paradigm

- Are we meeting the needs of our patients?
- What does the industry need?
- How can we change the manufacturing paradigm to meet the needs of our patients?

MilliporeSigma

Guillaume Plane
Global Development Manager
End-to-End Solutions.

INNOVATION SPOTLIGHTS

Ballroom: Consitution

Ballroom: Faneuil

BIOMANUFACTURING 4.0

TBA

13:30

CELL LINE DEVELOPMENT

Henry Chiou
Director of Product Management,
Protein Expression & Transfection

Title:
Highly automated and innovative Manufacturing analytical solutions: Find out how to automatically reveal and quantify undesired process outcomes.

Title:
Advancing AVV cell lines Expression System for cell therapies.

ThermoFisher SCIENTIFIC

PROGRAM: DAY 2 AFTERNOON - SESSIONS AND WORKSHOPS

14:15

STREAM KEYNOTE	STREAM KEYNOTE	STREAM KEYNOTE
4.0 ANALYTICS, AUTOMATION, SUPPLY CHAIN	**GENE THERAPY**	**BIOPROCESSING & MANUFACTURING**
TBA	**TBA**	**TBA**
Dynamic Supply Chain Resilience: Leveraging Digital Innovation for Agile Response to Market Fluctuations and Unforeseen Challenges	Revolutionizing Process Development: Preparing for the Commercial Scale-Up and Manufacturing of the First Approved Gene Editing Therapy	Addressing viral vector capacity dilemma: Evaluating the unique challenges in the manufacturing of viral vectors. How to developing scalable and cost-efficient manufacturing processes. Examining GMP compliance and what requirements need to be met; ensuring products are well-characterized and manufactured to high purity, efficacy, and safety

14:45

Dave Kolwyck VP Manufacturing Science Raw Materials	**Shawn Liu Ph.D** President & CEO	**Larry Sun** Director Upstream Processing
Implementation of “End to End” process control from raw materials to protein product quality enabling Pharma 4.0 manufacturing. Advances in integrating raw material characterization and handling operations with our strategic suppliers.	High titer and Quality AAV production, AAV analytics and AAV viral safety •	Process Intensification And Manufacturing Strategies For CAR-T Therapies. Demonstrating the consistent and scalable expansion of CAR-T cells from multiple donors in stirred- tank bioreactors. Approaches to reduce the variability and scalability issues of advanced therapies. Establishment of a control strategy for CAR-T process intensification.

15:15 **Afternoon Refreshments - Served at the Exhibition Area**

14:45

TBA	**Dr. Fulvio Mavilio** Scientific Director	**Jianmei Kochling,** Director, Analytical MSAT Global Manufacturing
Digital Transformation Tactics & Strategies Driving Performance in Biopharmaceutical Manufacturing through Digital Analytical and Automation Innovation.	Comparing and contrasting lentiviral, retroviral and other emerging cell transfection approaches for ex vivo gene therapy .	Preventing product variation and maintaining quality: Forced-degradation study challenge and strategy for biologics comparability studies, monitoring aggregation, characterization, stability and qualification.

PROGRAM: DAY 2 AFTERNOON

Ballroom: Consitution	Ballroom: Faneuil	Ballroom: Quincy
SUPPLY CHAIN LOGISTICS	**GENE THERAPY**	**BIOPROCESSING TECHNOLOGY & MANUFACTURING STRATEGY**
16:00		
TBA	**TBA**	**TBA**
Addressing supply chain strengths and weaknesses to create better production planning for lifecycle management : How ready is the industry for the tidal wave of biopharma demand? Examining specific product categories and their associated supply risks. From clinical to launch: Best techniques for demand and uncertainty	Successful tech transfer of gene and cell therapy products: exploring the differences/risks particular to these products	Revolutionizing Autologous Cell Therapy Production: An Autonomous Biomanufacturing Platform for Scalable and Efficient Generation of iPSC-Derived Therapies

16:30 **Closing Keynote**

Innovation as an avenue to pursue, to drive bioprocess performance up and cost down. **TBA**

17:00 **Reflections on the Congress**

Program Chairman

Dr. Aleš Štrancar

Managing Director

SARTORIUS | BIA separations

BIA Separations is now part of Sartorius

17:10 **Closing Comments - Weiser West Research**

VENUE

A world class venue in Boston will Cell & Gene Therapy Development, Innovation Summit 2025.
Modern Era leadership networking platform provides the perfect ambiance for leaders to congregate, bringing together the smartest people to share their experience, ideas, innovations and expertise. Access the right intelligence and technologies to design your future with robust strategies in confidence.



> *A major global hub, Boston has a unique Cell and Gene DNA and culture; one that is collaborative in nature*

EXCLUSIVELY INVITES INFLUENTIAL SENIOR LEVEL EXECUTIVES WITH THE HIGHEST CREDENTIALS

Selection of pioneering leaders

COMPANY	TITLE
Abbvie	Director Engineering Operations
Abbvie	Head of Microbial Manufacturing
Actogenix	Director CMC Operations
Actogenix	Director Of Manufacturing
Ark Therapeutics	Director Supply Chain
Adello Biologics	CSO
Agensys	Director, Quality
Astrazeneca	Senior Director, Immuno-Oncology, Global Medicines Development
Austrian Centre of Biotechnology	Laboratory of Cell Gene Technology
Baxter	Manager Cell Gene Therapy
Baxter AG	Project Team Leader Upstream Development
Baxter BioScience	Senior Director Operational Excellence
Bayers Global Biological Development	Director of Isolation & Purification
Bayers Global Biological Development	Senior Manager, Cell Gene Therapy
Biogen Idec	VP Techincal Development
Biogen Idec	VP Supply Chain
Boehringer Ingelheim	Director of Downstream Process Development
Boehringer Ingelheim	Associate Director Upstream Processing Technology
BMS	Head of Cell Gene Therapy Production
BMS	Director Operational Technical Support
Crucell	Director, Quality Control
Crucell	VP Process Development
Cytheris SA	Director of Process Development
Cytheris SA	Director Development of Chemical and Bio-Chemical
Cancer Research UK	Head of Biotherapeutics Development Unit
CHR Hansen	Director Supply Chain
CHR Hansen	General Manger

COMPANY	TITLE
CHR Hansen	Senior Director Bio Process
Chugai Pharmaceuticals	Associate Director Manufacturing Science and Technologies
Chugai Pharmaceuticals	Associate Director Process Development
Coretherapix	Head of Cell & Gene Technology
Dimension Therapeutics	Head of Development
Eli Lilly	Director Quality & Compliance
Eli Lilly	Manager, Upstream Technology
Elan	Senior Director Technology & Operation
EMEA	Director Quality Assessment
FDA	Director
EMD Serono	Downstream Manager
Genentech	VP, Operational Excellence
Genzyme	Director, Cell & Gene Therapy
Glaxo Smith Kline	Head of Downstream Processing, Biopharm Process Research
Glaxo Smith Kline	Head of Gene Therapy
Glaxo Smith Kline	Director, Operational Excellence
Glaxo Smith Kline	Director Quality Technologies & QbD Implementation
Hospira	Director Global Biologics
Institue of Operational Excellence	Founder
Jansen BV	Section Leader, Upstream Process Development,
Jansen BV	Snr Tech Director
Jansen BV	Senior Manager Purification
Lek Pharmaceuticals	Head of Innovation DSP Development
Lek Pharmaceuticals	Upstream Manufacturing Manager
Lonza	Associate Director, Process Transfer and Development
Lonza	Head of PCP, Exclusive Synthesis
Macrogenics	Quality Director
FDA	Associate Director
FDA	Senior Director Technical Operations
Medimmune	Assoc. Director for Manufacturing Science and Technology
Medimmune	Director Operational Excellence
Medimmune	Director, Supply Chain
Merck	Senior Manager, Expression & Purification.
Merck	Director Cultivation Stem Cell Manufacturing
Merck	Senior Manager, Protein Expression & Purification.
Merck	Director Cultivation Biopharmaceutical Manufacturing
UniQure	VP Regulatory Compliance

COMPANY	TITLE
Mylan	Vice-President and Head of Global Biologics Research & Development
Merck Serano	Bioprocess & Innovation Manager
Merck Serano	Director of Technical Development Biosimilars
Merck Serano	Principle Scientist Upstream Fermentation
Miltenyi Biotec GmbH	VP Supply Chain
Miltenyi Biotec GmbH	Project Manager R & D Bioprocess Sciences
Miltenyi Biotec GmbH	Head of R&D Recombinant Proteins
NovoNordisk	Director Raw Materials
NovoNordisk	Director, Process Development
Octapharma	Head of Upstream Processing Unit
Novartis	Lab Head, Novartis Vaccines and Diagnostics
Novartis	Director Bioprocess Development
Novartis	Principle Scientist Purification
Novartis	Director Supply Chain
Pfizer	Site Cell Culture Lead
Pfizer	Site Purification Lead
Pfizer	Director Quality Assurance
Pfizer	Biological CoE Director
Pfizer	Site OE Lead, Pfizer Global Manufacturing
Pfizer	Senior Director of Cell Line Development
Regeneron	Senior Director, Process Development
Regeneron	Director, Process Development
Resentia	Senior VP Process Development & Manufacturing
Roche	Operations Director
Roche	Purification Manager
Roche	Head of Cell Culture
Sandoz	Head of DSP Development Cell Culture
Sanofi	VP Process Development
Sanofi Pasteur	VP Global Manufacturing Technology
Sisene	Manager Purification
Shire	Associate Director, Cell Culture Development
SOBI	Senior Scientist Downstream Processing
Statens Serum Institut A/S	Director, Downstream Processing
Takada	Director, Manufacturing Science & Technology
Takada	Head of BioProcess
Theravectys	CSO
UniQure	VP Regulatory Compliance
UCB	Director, Process Development

REGISTER

Book Online: www.cgt-development.com/delegate-package.html

Tel : +44 (0) 203 699 8500
Email : delegates@wwresearch.net
Mail : Weiser West Research, 25 Cabot Square, London E14 4QZ.

SPECIAL DISCOUNTS

- **15% discount – 2 delegates**
- **20% discount – 3 delegates**
- **25% discount – 4 or more delegates**

Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

VENUE

The Marriot Waterfront, Boston, USA

to CGT-development Innovation Summit Delegates:
Up to 40% off room rates!

For enquires feel free to contact us:
+44 (0) 203 699 8500

DELEGATE PACKAGE SUMMARY

- Access To Over 60 Presentations
- Scheduled Master-Class & Workshops
- One Delegate Pass
- Networking Meetings
- Gala Dinner
- Full Hospitality For Both Days.

Delegate Fee: £1650

cgt-development
GLOBAL INNOVATION CONGRESS 2025

Weiser West Research produces and manages leading global summits Exclusively for the Pharmaceutical and Life Science industry.

We aim in help pioneering leaders boost success and growth by providing the perfect modern era networking platform that is highly informative and delivers a dynamic cohesive environment to benchmark, learn, engage, procure and interact at the very highest level.

www.wwresearch.net

Rene Labatut
Vice President
Biologics Technology
Innovation Strategy

sanofi

“Great Content. First Class Networking and Service”